Recombinant rabies virus compositions
AssigneeThomas Jefferson University
InventorsBernhard Dietzschold, Marie Luise Faber, Matthias Schnell, Milosz Faber
Life of this patent
Estimating the term…
Loading patent…
AssigneeThomas Jefferson University
InventorsBernhard Dietzschold, Marie Luise Faber, Matthias Schnell, Milosz Faber
Estimating the term…
Recombinant rabies viruses in which the arginine residue of the glycoprotein (G) at amino acid position 333 is exchanged, renders these viruses nonpathogenic for immunocompetent mammals regardless of the route of infection. Some of these recombinant rabies viruses after several serial virus passages in newborn mice can become pathogenic for adult mice. The reversion to the pathogenic phenotype is associated with a thymidine to adenosine mutation (T→A) at position 639 of the G gene, which results in an asparagine to lysine exchange at position 194 of G. The codon at position 637-639 was changed by site directed mutagenesis to replace asparagine at position 194 by an amino acid that minimized the possibility for an Asn→Lys exchange at amino acid position 194 of G and prevents reversion to a pathogenic form of the virus.
A non-pathogenic recombinant rabies virus comprising a mutated G gene that encodes a rabies virus glycoprotein wherein the amino acid 194 is serine and the amino acid 333 is glutamic acid in the glycoprotein.
A recombinant rabies virus expressing a glycoprotein comprising at least one glycoprotein gene sequence of SEQ ID NO 5.
A modified glycoprotein gene comprising SEQ ID NO 5.
Dependencies are inferred from the claim text.